Edition:
United States

Apricus Biosciences Inc (APRI.O)

APRI.O on Consolidated Issue listed on NASDAQ Capital Market

0.36USD
25 Jul 2016
Change (% chg)

-- (--)
Prev Close
$0.36
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
472,963
52-wk High
$1.99
52-wk Low
$0.30

Latest Key Developments (Source: Significant Developments)

Apricus Biosciences enters into common stock purchase agreement with Aspire Capital
Wednesday, 6 Jul 2016 08:00am EDT 

Apricus Biosciences Inc : Apricus Biosciences enters into common stock purchase agreement with Aspire Capital . Aspire Capital will complete an initial purchase of 2.5 million shares of common stock for proceeds of $1.0 million .Aspire Capital to purchase up to $6 million in additional shares of common stock over next 24 months.  Full Article

Apricus Biosciences reports Q1 loss per share of $0.05
Monday, 9 May 2016 07:12am EDT 

Apricus Biosciences Inc : To continue to reduce operating expenses with goal of achieving reductions of about 30% in 2016, 60% in 2017 compared to 2015 . Apricus biosciences provides corporate update and first quarter financial results . Q1 loss per share $0.05 . Q1 revenue $600,000 versus $500,000 . Q1 revenue view $922,000 -- Thomson Reuters I/B/E/S .Q1 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S.  Full Article

Apricus Biosciences Inc announces $10 mln registered direct offering
Wednesday, 13 Jan 2016 07:00am EST 

Apricus Biosciences Inc:Announces $10 million registered direct offering.Agreements with certain institutional investors for 11.4 million shares of common stock and warrants to buy up to 5.7 million shares.  Full Article

Apricus Biosciences Inc reports top-line phase 2a data for Rayva its topical treatment for raynaud's phenomenon
Thursday, 17 Sep 2015 07:00am EDT 

Apricus Biosciences Inc:Press release - Apricus reports top-line phase 2a data for Rayva(TM), its topical treatment for raynaud's phenomenon.Says there were no significant safety or tolerability issues observed in any dosing cohort.Says intends to move rayva into a later stage phase 2 clinical trial in 2016.There were subjects who demonstrated improvements in blood flow and/or hand temperature across all dosing cohorts.Believes this data, with previously generated non-clinical data, supports moving rayva forward into future clinical trials.  Full Article

Apricus Biosciences enters into license agreement with Allergan for the U.S. Rights to Vitaros
Thursday, 10 Sep 2015 07:00am EDT 

Apricus Biosciences Inc:Announces that it has licensed the U.S. development and commercialization rights for Vitaros from Allergan.Says under the license agreement, Apricus will be responsible for all Vitaros development efforts in the United States.  Full Article

Apricus Biosciences Inc announces approval of Vitaros for treatment of Erectile Dysfunction in Twelve Additional Countries
Monday, 10 Aug 2015 07:00am EDT 

Apricus Biosciences Inc:SASY Vitaros, topical cream indicated for treatment of patients with erectile dysfunction ("ED"), has been approved through European Decentralized Procedure ("DCP") in twelve additional countries.Those countries are: Austria, Cyprus, the Czech Republic, Denmark, Finland, Greece, Iceland, Norway, Poland, Portugal, Romania and the Slovak Republic.Apricus' commercialization partners that hold license for these additional territories will be responsible for the next step of obtaining national phase approvals in order to make Vitaros ready to launch.  Full Article

Apricus Biosciences Inc announces issuance of U.S. patent for RayVa
Tuesday, 27 Jan 2015 04:30pm EST 

Apricus Biosciences Inc:Says that Jan. 27, United States Patent and Trademark Office (USPTO) issued to Apricus, U.S. Patent No. 8,940,794, titled "METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE," with claims generally directed to methods for treating Raynaud's phenomenon, that is secondary to systemic sclerosis.Patent is expected to expire no earlier than twenty-year term in 2032.RayVa is proprietary name for Apricus' product candidate for treatment of Raynaud's phenomenon.  Full Article

Apricus Biosciences Inc announces resignation of CFO - Form 8-K
Monday, 15 Dec 2014 04:06pm EST 

Apricus Biosciences Inc:Says on Dec. 12, 2014, Steve Martin tendered his resignation as the senior vice president, chief financial officer and secretary, such resignation to be effective immediately.  Full Article

Apricus Biosciences Inc announces launch of Vytaros
Monday, 3 Nov 2014 06:00am EST 

Apricus Biosciences Inc:Says launch of Vytaros in Belgium by Sandoz Division of Novartis Group of companies.Says novel topical on-demand treatment for erectile dysfunction ("ED"), being marketed in Belgium as Vytaros, is also marketed in other European countries as Vitaros.Product is currently approved in ten countries in Europe, including major ED markets such as aforementioned and France, Italy and Spain.Says company expects additional launches by its partners in these approved countries into 2015.  Full Article

Apricus Biosciences, Inc expands development pipeline with in licensing of U.S. Rights for Fispemifene
Monday, 20 Oct 2014 02:00am EDT 

Apricus Biosciences, Inc:Says that it has licensed the U.S. development and commercialization rights for a novel selective estrogen receptor modulator (SERM), fispemifene, an investigational treatment for urological conditions in men, from Forendo Pharma, a private therapeutics company based in Finland.Says this license agreement combines Apricus' expertise in men's health with Forendo's established leadership in SERM drug discovery, to advance the development of fispemifene as an investigational treatment for urological conditions in men.  Full Article

BRIEF-Apricus Biosciences expands existing partnership with Ferring Pharmaceuticals

* Apricus biosciences inc says apricus and sandoz agree to mutually terminate license agreement